Physician profile
Divya Chand Mitchell
NPI 1487323994
$1,103.27
in general payments reported to CMS, 2019-2025
22 companies · $594 in 2025
The $594 reported for 2025 was more than what 78% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $174 · 2023: $314 · 2024: $20.93 · 2025: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $808 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $808.27 |
| Education | $120.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $165.94 | 2025 | Lynparza, Imfinzi |
| Merck Sharp & Dohme LLC | $141.58 | 2025 | Keytruda, Keytruda Qlex, Lynparza |
| Kite Pharma, INC. | $124.37 | 2023 | |
| Seagen INC. | $122.70 | 2023 | Tukysa |
| Novartis Pharmaceuticals Corporation | $93.58 | 2022-2025 | |
| Gilead Sciences, INC. | $45.01 | 2023-2025 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $43.77 | 2022 | |
| Genentech USA, INC. | $43.26 | 2025 | Itovebi, Polivy |
| Eisai INC. | $41.18 | 2025 | |
| Pfizer INC. | $30.42 | 2022 | |
| Novo Nordisk INC | $30.21 | 2022 | |
| Coherus Oncology, INC. | $27.43 | 2025 | Loqtorzi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.97 | 2025 | |
| Alexion Pharmaceuticals, INC. | $24.61 | 2025 | Ultomiris |
| Opko Pharmaceuticals, LLC | $21.66 | 2023 | Rayaldee |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $21.32 | 2025 | Krystexxa |
| Tempus Ai, INC | $20.93 | 2024 | |
| Astellas Pharma US INC | $20.71 | 2025 | Vyloy |
| Azurity Pharmaceuticals, INC. | $17.73 | 2025 | Danziten |
| Caris Mpi, INC. | $16.02 | 2025 | Mi Cancer Seek |
| Immunogen, INC. | $14.58 | 2023 | Elahere |
| Aadi Bioscience, INC. | $11.29 | 2023 | Fyarro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Divya Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.